Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
Brief Summary: This study was to assess whether sofosbuvir in combination with ribavirin (RBV) and pegylated interferon alfa 2a (PEG) administered for 12 weeks is safe and effective in patients with hepatitis C virus (HCV) genotypes 1, 4, 5 , or 6 as assessed by the rate of sustained viral response (SVR) 12 weeks after discontinuation of therapy (SVR12).


Options:
A: Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin | Intervention Type: BIOLOGICAL; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week
B: Arm Label: Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV; Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325, Drug: Ribavirin | Intervention Type: DRUG; Name: BMS-650032; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: BMS-790052; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV
C: Arm Label: Sofosbuvir+PEG+RBV; Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: RBV, Drug: PEG | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Sofosbuvir+PEG+RBV | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): Sofosbuvir+PEG+RBV
D: Arm Label: Placebo+PEG2b+RBV, x 44 weeks; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pegylated interferon alfa-2b (SCH 54031), Drug: Ribavirin (SCH 18908), Drug: Boceprevir placebo | Arm Label: Boceprevir+PEG2b+RBV, Response Guided Therapy; Type: EXPERIMENTAL; Interventions: Drug: Boceprevir (SCH 503034), Biological: Pegylated interferon alfa-2b (SCH 54031), Drug: Ribavirin (SCH 18908), Drug: Boceprevir placebo | Arm Label: Boceprevir+PEG2b+RBV, x 44 weeks; Type: EXPERIMENTAL; Interventions: Drug: Boceprevir (SCH 503034), Biological: Pegylated interferon alfa-2b (SCH 54031), Drug: Ribavirin (SCH 18908) | Intervention Type: DRUG; Name: Boceprevir (SCH 503034); Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Boceprevir+PEG2b+RBV, x 44 weeks | Intervention Type: BIOLOGICAL; Name: Pegylated interferon alfa-2b (SCH 54031); Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Boceprevir+PEG2b+RBV, x 44 weeks, Placebo+PEG2b+RBV, x 44 weeks | Intervention Type: DRUG; Name: Ribavirin (SCH 18908); Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Boceprevir+PEG2b+RBV, x 44 weeks, Placebo+PEG2b+RBV, x 44 weeks | Intervention Type: DRUG; Name: Boceprevir placebo; Assigned to Arm(s): Boceprevir+PEG2b+RBV, Response Guided Therapy, Placebo+PEG2b+RBV, x 44 weeks

Answer: C